AR106113A1 - DERIVATIVES OF 2,3,4,5-TETRAHYDROPIRIDIN-6-AMINA - Google Patents

DERIVATIVES OF 2,3,4,5-TETRAHYDROPIRIDIN-6-AMINA

Info

Publication number
AR106113A1
AR106113A1 ARP160102894A ARP160102894A AR106113A1 AR 106113 A1 AR106113 A1 AR 106113A1 AR P160102894 A ARP160102894 A AR P160102894A AR P160102894 A ARP160102894 A AR P160102894A AR 106113 A1 AR106113 A1 AR 106113A1
Authority
AR
Argentina
Prior art keywords
alkyloxy
alkyl
cyclopropyl
monohalo
cyclopropyloxy
Prior art date
Application number
ARP160102894A
Other languages
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR106113A1 publication Critical patent/AR106113A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de 2,3,4,5-tetrahidropiridin-6-amina inhibidores de b-secretasa. También se refiere a composiciones farmacéuticas que comprenden tales compuestos, a procesos para preparar tales compuestos y composiciones, y al uso de tales compuestos y composiciones para prevenir y tratar trastornos en los que participa la b-secreta, tales como la enfermedad de Alzheimer (EA), el deterioro cognitivo leve, senilidad, demencia, demencia con cuerpos de Lewy, síndrome de Down, demencia asociada con el accidente cerebrovascular, demencia asociada con la enfermedad de Parkinson o demencia asociada con b-amiloides. Reivindicación 1: Un compuesto de formula (1) o un tautómero o forma estereoisomérica de este, donde R¹ se selecciona del grupo que consiste en -alquilo C₁₋₃, -alquilo C₁₋₃-F y flúor; R² se selecciona del grupo que consiste en -SO₂-alquilo C₁₋₃, -SO₂-ciclopropilo, -CN, -O-alquilo C₁₋₃, CF₃ y SO(NCH₃)CH₃; Ar es homoarilo o heteroarilo; en donde homoarilo es fenilo o fenilo sustituido con uno, dos o tres sustituyentes, seleccionados cada uno independientemente entre el grupo que consiste en halo, ciano, alquilo C₁₋₃, ciclopropilo, alquiloxi C₁₋₃, ciclopropiloxi, (ciclopropil)alquiloxi C₁₋₃, monohalo-alquilo C₁₋₃ polihalo-alquilo C₁₋₃ monohalo-ciclopropilo, polihalo-ciclopropilo, monohalo-alquiloxi C₁₋₃, polihalo-alquiloxi C₁₋₃ monohalo-ciclopropiloxi, polihalo-ciclopropiloxi, (alquiloxi C₁₋₃)alquiloxi C₁₋₃, (ciclopropiloxi)alquiloxi C₁₋₃ y HCºCCH₂O; heteroarilo se selecciona del grupo constituido por piridilo, pirimidinilo, pirazinilo, piridazinilo, furanilo, tienilo, pirrolilo, pirazolilo, imidazolilo, triazolilo, tetrazolilo, tiazolilo, isotiazolilo, tiadiazolilo, oxazolilo, isoxazolilo y oxadiazolilo, cada uno opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados cada uno independientemente del grupo que consiste en halo, ciano, alquilo C₁₋₃, ciclopropilo, alquinilo C₂₋₃, alquiloxi C₁₋₃, ciclopropiloxi, (ciclopropil)alquiloxi C₁₋₃, monohalo-alquilo C₁₋₃, polihalo-alquilo C₁₋₃, monohalo-ciclopropilo, polihalo-ciclopropilo, monohalo-alquiloxi C₁₋₃, polihalo-alquiloxi C₁₋₃, monohalo-ciclopropiloxi, polihalo-ciclopropiloxi, (alquiloxi C₁₋₃)alquiloxi C₁₋₃, (ciclopropiloxi)alquiloxi C₁₋₃ y HCºCCH₂O; R³, R⁴, R⁵, y R⁶ se seleccionan cada uno independientemente del grupo que consiste en H, flúor, metilo y metoxi; y R⁷ es hidrógeno o flúor; o un solvato o una sal de adición farmacéuticamente aceptables de este.Compounds of 2,3,4,5-tetrahydropyridin-6-amine b-secretase inhibitors. It also refers to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions to prevent and treat disorders in which b-secretion participates, such as Alzheimer's disease (AD). ), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with b-amyloid. Claim 1: A compound of formula (1) or a stereoisomeric tautomer or form thereof, wherein R¹ is selected from the group consisting of -C₁₋₃ alkyl, -C₁₋₃-F alkyl and fluorine; R² is selected from the group consisting of -SO₂-C₁₋₃ alkyl, -SO₂-cyclopropyl, -CN, -O-C₁₋₃ alkyl, CF₃ and SO (NCH₃) CH₃; Ar is homoaryl or heteroaryl; wherein homoaryl is phenyl or phenyl substituted with one, two or three substituents, each independently selected from the group consisting of halo, cyano, C₁₋₃ alkyl, cyclopropyl, C₁₋₃ alkyloxy, cyclopropyloxy, (cyclopropyl) C₁₋ alkyloxy ₃, monohalo-C₁₋₃ alkyl polyhalo-C₁₋₃ alkyl monohalo-cyclopropyl, polyhalo-cyclopropyl, monohalo-C alquilo alkyloxy, polyhalo-C₁₋₃ monohalo-cyclopropyloxy, polyhalo-cyclopropyloxy, (C₁₋₃ alkyloxy) C₁₋₃, (cyclopropyloxy) C₁₋₃ alkyloxy and HCCCH₂O; heteroaryl is selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl and oxadiazolyl, each optionally substituted with two three substituents each independently selected from the group consisting of halo, cyano, C₁₋₃ alkyl, cyclopropyl, C₂₋₃ alkynyl, C₁₋₃ alkyloxy, cyclopropyloxy, (cyclopropyl) C₁₋₃ alkyloxy, monohalo-C₁₋₃ alkyl, polyhalo -C₁₋₃ alkyl, monohalo-cyclopropyl, polyhalo-cyclopropyl, monohalo-C₁₋₃ alkyloxy, polyhalo-C₁₋₃ alkyloxy, monohalo-cyclopropyloxy, polyhalo-cyclopropyloxy, (C₁₋₃ alkyloxy), (cyclopropyloxy) C₁₋₃ alkyloxy and HCºCCH₂O; R³, R⁴, R⁵, and R⁶ are each independently selected from the group consisting of H, fluorine, methyl and methoxy; and R⁷ is hydrogen or fluorine; or a pharmaceutically acceptable solvate or addition salt thereof.

ARP160102894A 2015-09-23 2016-09-22 DERIVATIVES OF 2,3,4,5-TETRAHYDROPIRIDIN-6-AMINA AR106113A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15186394 2015-09-23

Publications (1)

Publication Number Publication Date
AR106113A1 true AR106113A1 (en) 2017-12-13

Family

ID=54196872

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102894A AR106113A1 (en) 2015-09-23 2016-09-22 DERIVATIVES OF 2,3,4,5-TETRAHYDROPIRIDIN-6-AMINA

Country Status (1)

Country Link
AR (1) AR106113A1 (en)

Similar Documents

Publication Publication Date Title
SV2018005655A (en) "DERIVATIVES OF 8- [6- [3- (AMINO) PROPOXI] -3-PIRIDIL] 1-ISOPROPILIMIDAZO [4,5-C] QUINOLIN-2-ONA AS SELECTED MODULATORS OF THE MUTED TELANGIECTASIA ATAXIA KINASE (ATM) FOR THE TREATMENT OF CANCER "
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
UY36112A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER
AR089671A1 (en) 1,4-DIHIDROPIRIMIDINAS 4,4-DISUSTITUIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
CL2017001017A1 (en) New methyl piperidine compounds useful for inhibiting microsomal e2 prostaglandin synthase-1
AR105648A1 (en) METHODS FOR THE PREPARATION OF BILIARY ACIDS AND DERIVATIVES OF THE SAME
SV2018005663A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT
CO2017003279A2 (en) Pharmaceutically acceptable compounds and compositions thereof, effective as mk2 inhibitors
CU24517B1 (en) SUBSTITUTE CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTINEOPLASTIC AGENTS
EA201691471A1 (en) MACRO CYCLES WITH P2 'HETEROCYCLIC GROUPS AS AN INHIBITORS OF XIA FACTOR
AR108046A1 (en) INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE
PE20191245A1 (en) THIAZOLCARBOXAMIDES AND PYRIDINACARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
NZ631027A (en) Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
AR106865A1 (en) PIRIDINES REPLACED AND METHODS OF USE
CU24355B1 (en) DERIVATIVES OF 2 (((OXADIAZOL / TRIAZOL / TETRAZOL / ISOXAZOL) METHYL) PHENYL) -1- (HETEROCICLYL) -ONE AS ACTIVE AUTOTAXIN INHIBITORS
AR107170A1 (en) TRICYCLIC HETEROCYCLIC COMPOUNDS CONDEMATED AS HIV INTEGRAS INHIBITORS
MX2016012451A (en) 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives.
CU20160073A7 (en) 2.6 USED SUBSTITUTED PURINS IN THE TREATMENT OF PROLIFERATIVE DISORDERS SUCH AS CANCER
EA201691670A1 (en) TETRASOLONETRESSED DIHYDROPYRIDINOUM INHIBITORS MGAT2
CU20170007A7 (en) IMIDAZOPIRIDAZINE COMPOUNDS
NI201800071A (en) ISOINDOL COMPOUNDS
NI201600176A (en) COMPOUNDS OF 1, 3, 4 - TIADIAZOLE AND THE USE OF THEM FOR THE TREATMENT OF CANCER.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
AR107937A1 (en) CINOLIN-4-AMINA COMPOUNDS AND ITS USE IN CANCER TREATMENT
AR103264A1 (en) DERIVATIVES OF 3,5-AMINOPIRAZOL AS INHIBITORS OF QUINASA RC

Legal Events

Date Code Title Description
FB Suspension of granting procedure